On Aug. 18, 2020, Regeneron and Roche announced that they had joined forces in the fight against COVID-19 to develop, manufacture and distribute REGN-COV2, Regeneron’s investigational anti-viral antibody cocktail, to people around the globe.

REGN-COV2 could provide a much-needed treatment option for people already experiencing symptoms of COVID-19, and also has the potential to prevent infection in people exposed to the virus, thus slowing the spread of the global pandemic.